The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 18, 2017

Filed:

Mar. 23, 2015
Applicants:

Novo Nordisk A/s, Bagevaerd, DK;

Innate Pharma, Marseilles, FR;

Inventors:

Søren Berg Padkær, Vaerlose, DK;

Peter Andreas Nicolai Reumert Wagtmann, Cassis, FR;

Petrus Johannes Louis Spee, Allerød, DK;

Stefan Zahn, Steuløse, DK;

Kristian Kjærgaard, Ballerup, DK;

Anders Svensson, Malmö, SE;

Assignees:

NOVO NORDISK A/S, Bagevaerd, DK;

INNATE PHARMA, Marseille, FR;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C12P 21/04 (2006.01); C07H 21/00 (2006.01); C12P 15/00 (2006.01); C12N 15/00 (2006.01); C07K 16/28 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2803 (2013.01); C07K 16/28 (2013.01); C07K 2299/00 (2013.01); C07K 2316/96 (2013.01); C07K 2317/55 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01);
Abstract

The present invention relates to agents and methods that are capable of augmenting NK-mediated killing of target cells by reducing inhibitory KIR signalling without reducing the binding of KIR to HLA-C. As described herein, transduction of negative signaling via KIR, upon binding of KIR to its HLA class I ligand, can involve a ligand-binding induced, conformational reorientation of the KIR molecules allowing interactions to form between adjacent KIRs in specific domains, leading to accelerated clustering. Methods and agents such as monoclonal antibodies for reducing KIR-mediated inhibition of NK cell cytotoxicity without reducing or blocking HLA-binding by, e.g., reducing or blocking dimerization of KIR, are provided.


Find Patent Forward Citations

Loading…